新鲜囊胚期胚胎移植后单胎活产的围产期结局:一项基于67 147个IVF/ICSI周期的回顾性分析
该回顾性队列研究基于英国HFEA 1999至2011年数据,比较新鲜囊胚期与卵裂期胚胎移植后单胎活产的围产期结局。囊胚期移植不增加早产、低/高出生体重或先天异常风险,不改变出生性别比或健康婴儿几率;亚组分析中囊胚期移植的先天异常风险显著较高。
要点
- 囊胚期移植不增加早产、低/高出生体重风险,健康婴儿几率无改变。
- 主要分析中先天异常风险无显著差异,但首次治疗亚组中囊胚期移植先天异常风险显著较高。
- 主要分析中囊胚期移植男婴几率略微增加,但首次治疗亚组中无显著差异。
核心结论
- 新鲜囊胚期胚胎移植不增加早产、低/高出生体重或先天异常风险,不改变出生性别比或健康婴儿几率。
研究设计与样本
- 基于英国人类受精与胚胎学管理局(HFEA)1999至2011年匿名周期数据的回顾性队列研究,共纳入67 147个IVF/ICSI周期,其中囊胚期移植11 152个周期,卵裂期移植55 995个周期。
主要发现
- 囊胚期组与卵裂期组早产风险无显著差异(aRR 1.00,99.5%CI 0.79-1.25),极早产风险无显著差异(aRR 1.00,99.5%CI 0.63-1.54)。
- 极低出生体重风险无显著差异(aRR 0.84,99.5%CI 0.53-1.34),低出生体重风险无显著差异(aRR 0.92,99.5%CI 0.73-1.16)。
- 高出生体重风险无显著差异(aRR 0.94,99.5%CI 0.75-1.18),极高出生体重风险无显著差异(aRR 1.05,99.5%CI 0.66-1.65)。
- 囊胚期组先天异常风险较卵裂期组高16%,但未达统计学显著(aRR 1.16,99.5%CI 0.90-1.49)。
- 健康婴儿(足月、出生体重正常且无先天异常)几率无显著改变(aRR 1.00,99.5%CI 0.93-1.07);主要分析中男婴几率略微增加(aRR 1.04,99.5%CI 1.01-1.09),首次治疗亚组中无显著差异(aRR 1.04,95%CI 1.00-1.08)。
关键数值与推荐
- 首次IVF/ICSI治疗亚组中,囊胚期移植后先天异常风险显著较高(aRR 1.42,95%CI 1.12-1.81)。
临床怎么用
- 作者认为,研究结果应能让接受囊胚期胚胎移植的女性放心;作者首次显示囊胚移植后出生的婴儿与卵裂期胚胎移植后出生的婴儿健康几率相似。
局限性
- 研究使用观察性数据,无法校正关键混杂因素,如母亲吸烟状态和体重指数(BMI),这些未记录在HFEA数据集中。
- 主要分析基于周期,无法链接同一女性进行的多个IVF/ICSI周期,因此对首次治疗周期的女性进行了亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are perinatal outcomes different between singleton live births conceived from fresh blastocyst transfer and those following the transfer of fresh cleavage-stage embryos? SUMMARY ANSWER: Fresh blastocyst transfer does not increase risks of preterm birth (PTB), low/high birth weight or congenital anomaly and does not alter the sex ratio at birth or prejudice the chance of having a healthy baby. WHAT IS KNOWN ALREADY: Extended embryo culture is currently considered the best option for embryo selection, but concerns have been raised about increased risks of preterm delivery and large-for-gestational-age (LGA) babies. STUDY DESIGN, SIZE, DURATION: We conducted a retrospective cohort study based on data from the Human Fertilisation and Embryology Authority (HFEA) anonymised and cycle-based dataset in the UK between 1999 and 2011. PARTICIPANTS/MATERIALS, SETTING, METHODS: Baseline characteristics were compared between in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) blastocyst-stage and cleavage-stage embryo transfer cycles using the χ2 test for categorical/dichotomised covariates and the Mann-Whitney test for continuous covariates. Statistical significance was set at <0.005. Poisson regression and multinomial logistic regression were used to establish relationships between perinatal outcomes and blastocyst-stage embryo transfer or cleavage-stage embryo transfer. Risk ratios (RRs), adjusted risk ratios (aRRs) and their 99.5% confidence intervals (CIs) were calculated as a measure of strength of associations. Results were adjusted for clinically relevant covariates. A sub-group analysis included women undergoing their first IVF/ICSI treatment. The level of significance was set at <0.05, and 95% CIs were calculated in the sub-group analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Of a total of 67 147 IVF/ICSI cycles, 11 152 involved blastocyst-stage embryo(s) and 55 995 involved cleavage-stage embryo(s). The two groups were comparable with regards to the risk of PTB (aRR, 1.00; 99.5% CI, 0.79-1.25), very-preterm birth (VPTB) (aRR, 1.00; 99.5% CI, 0.63-1.54), very-low birth weight (VLBW) (aRR, 0.84; 99.5% CI, 0.53-1.34), low birth weight (LBW) (aRR, 0.92; 99.5% CI, 0.73-1.16), high birth weight (HBW) (aRR, 0.94; 99.5% CI, 0.75-1.18) and very-high birth weight (VHBW) (aRR, 1.05; 99.5% CI, 0.66-1.65). The risk of congenital anomaly was 16% higher in the blastocyst-stage group than in the cleavage-stage group, but this was not statistically significant (aRR, 1.16; 99.5% CI, 0.90-1.49). The chance of having a healthy baby (born at term, with a normal birth weight and no congenital anomalies) was not altered by extended culture (aRR, 1.00; 99.5% CI, 0.93-1.07). Extended culture was associated with a marginal increase in the chance having a male baby in the main cycle-based analysis (aRR, 1.04; 99.5% CI, 1.01-1.09) but not in the sub-group analysis of women undergoing their first cycle of treatment (aRR, 1.04; 95% CI, 1.00-1.08). In the sub-group analysis, the risk of congenital anomalies was significantly higher after blastocyst-stage embryo transfer (aRR, 1.42; 95% CI, 1.12-1.81). LIMITATIONS, REASONS FOR CAUTION: This study is limited by the use of observational data and inability to adjust for key confounders, such as maternal smoking status and body mass index (BMI), which were not recorded in the HFEA dataset. As the main analysis was cycle-based and we were unable to link cycles within women undergoing more than one IVF/ICSI cycle, we undertook a sub-group analysis on women undergoing their first treatment cycle. WIDER IMPLICATIONS OF THE FINDINGS: Our findings should reassure women undergoing blastocyst-stage embryo transfer. For the first time, we have shown that babies born after blastocyst transfer have a similar chance of being healthy as those born after cleavage-stage embryos transfer. STUDY FUNDING/COMPETING INTEREST(S): The research activity of Dr Nicola Marconi was funded by the scholarship 'A. Griffini-J. Miglierina', Fondazione Comunitaria del Varesotto, Provincia di Varese, Italy. The authors do not have any competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.
引用
- Marconi N, Raja EA, Bhattacharya S, et al. Perinatal outcomes in singleton live births after fresh blastocyst-stage embryo transfer: a retrospective analysis of 67 147 IVF/ICSI cycles. Hum Reprod. 2019. PMID: 31418775. doi:10.1093/humrep/dez133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。